AST-OPC1
Phase 1/2Completed 0 watching 0 views this weekπ€ Quiet
33
Development Stage
β
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Spinal Cord Injury
Conditions
Cervical Spinal Cord Injury, Spine Injury, Spinal Cord Trauma
Trial Timeline
Mar 1, 2015 β Dec 1, 2018
NCT ID
NCT02302157About AST-OPC1
AST-OPC1 is a phase 1/2 stage product being developed by Lineage Cell Therapeutics for Cervical Spinal Cord Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT02302157. Target conditions include Cervical Spinal Cord Injury, Spine Injury, Spinal Cord Trauma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02302157 | Phase 1/2 | Completed |
Competing Products
20 competing products in Cervical Spinal Cord Injury